Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Ustekinumab: Phase III data

In the Phase III PHOENIX 2 trial in 1,230 patients, 67% and 76% of patients receiving 45 and

Read the full 180 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE